This editorial refers to 'Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry' † , by J. Brachmann et al., on page 1317.
Where we have been
Clinical cardiac electrophysiology (CCEP) as we know it today began half a century ago with the observation that a catheter electrode could be introduced into a blood vessel and positioned in the heart to record electrical activity from specific parts of the cardiac conduction system, initially the His bundle. 1, 2 The next 10 years of CCEP research focused on understanding the electrophysiology of tachyarrhythmias and determining their sites of origin. Among early observations were: the demonstration of dual atrioventricular (AV) nodal pathways as the foundation of AV nodal reentrant tachycardia (AVNRT); 3 both manifest 4 and concealed 5 WolffParkinson-White (WPW) electrophysiology explaining AV reentrant tachycardias (AVRTs); and mechanisms of ventricular tachycardias. 6 As so often happens in medicine, surgeons pioneer cardiac therapies; cardiologists follow and replace scalpels with catheters. Treatment of arrhythmias was no different. Surgeons demonstrated the initial successful surgical interruption of an accessory pathway for AVRT, 7 partial isolation of the AV node for AVNRT, 8 resection of ventricular tachycardia, 9 and abolition of atrial flutter and fibrillation. 10 Clinical cardiac electrophysiologists followed with catheter ablative techniques, progressing from delivering large shocks from a DC defibrillator, to more sophisticated applications of radiofrequency energy, 11 and to newer forms including cryoenergy, ultrasound, laser, and other energy sources.
Where we are
The study by Brachmann et al. 12 brings us to the present state of therapy for supraventricular tachycardias. They note that six patients per 10 000 of the world population annually receive catheter ablation procedures for different types of arrhythmias. The popularity of this technique is based on two factors: the lack of safe and effective drugs to control arrhythmias and the opportunity to cure a patient of his/ her problem. There are not many diseases in medicine that we can actually cure. I have been tempted to put a sign over our EP lab that says, 'We fix ECGs'. The present investigators explored the German registry that prospectively collected data on cardiac ablation procedures performed between January 2007 and January 2010 in 52 voluntarily participating German centres. While such a study suffers from lack of patient uniformity, for example each site decided on the ablation method, imaging technologies, energy source, and procedural endpoints, nevertheless the data provide real-world results in 12 566 patients undergoing ablation for atrial fibrillation (AF; 37.2%), atrial flutter (AFl; 29.9%), AVNRT (23.2%), AVRT (6.3%), and focal atrial tachycardia (AT; 3.4%) (Figure 1) . Just how 'real world' this study represents can be questioned when one looks at the outstanding acute results of the periprocedural success rate that equalled or exceeded 94%, except for focal AT (84.3%). One could question whether centres with less successful outcomes opted out of participating. Perhaps more real world was the re-ablation rate for symptomatic tachycardia recurrence that ranged from 3.5% for AVNRT to 19.4% for AF. A composite rate of death, stroke, and myocardial infarction ranged from none (AVRT and focal AT) to 0.3% (AF). After 1 year, 74.1% of interviewed patients perceived ablation therapy as successful, 15.7% as partly successful, and 9.6% as unsuccessful.
Where we are going
As good as these results are, and they are quite good, they still need improvement. As the authors note, the periprocedural success rate was high, but late arrhythmia recurrences affected one-third of patients and necessitated repeat ablation procedures in 12.0%. There are many reasons for late recurrences and they will never totally disappear. However, advances in imaging and ablation tools will further reduce that problem, as well as the complication rate.
While these are admirable goals, I have a larger, more disruptive objective in mind. In the not too distant future, I envisage a totally non-invasive ablation approach. Using advanced ECG 13 and cardiac imaging 14 technology, it is possible to construct patient-specific models of the arrhythmic substrate to identify non-invasively ablation targets likely to eliminate the arrhythmia. Then, using a transcutaneous focused energy delivery source, such as laser, ultrasound, or stereotactic external beam radiation, 15 the area can be ablated, rendering the patient free of arrhythmia without a surgical procedure.
Pure fantasy? Perhaps, but I do not think so. In May 1961, President John F. Kennedy challenged the USA to land a man on the moon within the decade, 'not because it is easy, but because it is hard.' The same challenge could be offered to invasive electrophysiologists: fix ECGs non-invasively, certainly within the next decade, but hopefully within the next 5 years.
